InvestorsHub Logo
Post# of 252279
Next 10
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

Re: jq1234 post# 162652

Monday, 06/17/2013 9:29:12 PM

Monday, June 17, 2013 9:29:12 PM

Post# of 252279
I agree it's unfair to compare...

But I still maintain a "next generation" drug needs to show a 10% or better improvement in either ORR, PFS, or OS. And certainly not LDK's worse safety profile with more grade 3/4 AE's than Criz. Doesn't LDK's near equal ORR in Criz-resist and naive populations suggest mutations are being missed? But of course if AP26113 inhibits most mutants why is ORR at 75% against Chugai's 93%. I've heard some predicting '113 ORR will be higher at ESMO.

Regarding Criz I was referring to these studies:
Profile 1005 PH2 (ORR 61%) At least one prior line of chemo, 72% had 2 or more.
Profile 1007 PH3 (ORR 65%) All patients had received one prior chemo.

If Chugai data holds up I would consider it a true 2nd gen, and same for '113 with superior brain met activity and reasonable safety, if it holds ORR above 70% and shows PFS 10-20% better than Criz.





Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.